|
Synonyms: example 63 [WO2019149738A1] | HRX-0215 | HRX-215 | HRX215
Compound class:
Synthetic organic
Comment: This is the chemical structure for the INN darizmetinib. This structure is claimed in HepaRegeniX's patent WO2019149738A1, as a mitogen-activated protein kinase kinase 4 (MKK4) inhibitor [3]. The association of darizmetinib with HepaRegeniX's lead MKK4 inhibitor HRX215 was disclosed in May 2026 [1]. MKK4 is a key regulator of liver regeneration that operates predominantly via MKK7 and JNK1. Inhibition of MKK4 accelerates and enhances the liver's natural regenerative capacity [4].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Albrecht W, Selig R, Pfaffenrot B, Kloevekorn P, Juchum M, Zwirner S, Klotz S, Zender L, Laufer S. (2026)
Darizmetinib (HRX215): A Promising 1st-in-Class Liver Regenerating Drug in Phase 1b/2a Clinical Development, Targeting the Stress Signaling Protein Kinase MKK4. J Med Chem, 69 (10): 11687-11704. [PMID:42089702] |
|
2. FDA.
selective inhibitor of dual-specific protein kinase mitogen-activated protein kinase kinase 4 (MKK4). Accessed on 02/09/2026. Modified on 02/09/2026. www.accessdata.fda.gov, www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1140026 |
|
3. Praefke B, Klovekorn P, Selig R, Albrecht W, Laufer S. (2019)
Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death. Patent number: WO2019149738A1. Assignee: Heparegenix Gmbh. Priority date: 30/01/2019. Publication date: 08/08/2019. |
|
4. Zwirner S, Abu Rmilah AA, Klotz S, Pfaffenroth B, Kloevekorn P, Moschopoulou AA, Schuette S, Haag M, Selig R, Li K et al.. (2024)
First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure. Cell, 187 (7): 1666-1684.e26. [PMID:38490194] |